Trouble reading this email? View it in your browser
European Federation of Pharmaceutical industries and associations
   

EFPIA Newsletter 15 October 2020

 
 
 
   

Health after COVID-19: spend more but spend smarter
 
Nathalie Moll for the Parliament Magazine
As we enter the final stretch of 2020, we face a huge dilemma for public health and public finances: how do we manage the massive impact of COVID-19 and the increasing burden of chronic diseases without bankrupting public finances?

There is a growing recognition of the urgent need to invest more in making our health systems more resilient, and that strategic investments in healthcare infrastructures can play an important part in Europe’s economic recovery.


Read more


 
 
 
   

News
 

Strengthening health systems through smart spending
15 October 2020

EFPIA has developed a number of policy recommendations for national and European policy-makers to inform a discussion... Read more

Biopharmaceutical industry support EU regulators exceptional transparency measures
14 October 2020

And call other regulatory authorities to follow suit to help ensure confidence in the science and the decision-making... Read more
 
 
 
   

19 Conversations | The EFPIA podcast series
 

Podcast: Who decides the price of a medicine?
14 October 2020

Welcome to 19 conversations Read more
 
 
 
   

Videos
 
What is a rolling review?
EMA has started the rolling review of COVID-19 vaccines. What is a rolling review? We've asked it to our experts: Sini... Read more
Are we spending smart in healthcare?
According to the OECD, 20% of healthcare expenditure is spent inefficiently, making no meaningful contribution to patients’... Read more
 
 
 
   

Events
 

Everything You Always Wanted to Know About Drug Shortages (But were afraid to ask)
22 October 2020 (Virtual event)

How can we prevent drug shortages? First-hand insights from the supply chain Read more

NEW DATES - EU Health Summit 2020
26 October 2020 (Virtual event)

The EU Health Coalition is delighted to announce the second edition of the EU Health Summit. Read more

Orphan Medicines: how to sustain innovation in an area of high unmet need?
30 October 2020 (Virtual event)

For every case where a new treatment has been developed there are however many more rare diseases that still need treatment... Read more

Neuroscience Virtual Partnering
09 November 2020 (Virtual event)

Neurological disorders are one of the most feared diseases in the world – they affect almost a billion people worldwide... Read more

IMI Stakeholder Forum 2020
10 November 2020 (Virtual event)

The theme this year is 'Broader horizons: growing Europe’s health partnership'. Read more

Clinical Trial Disclosure & Data Transparency Conference
16 November 2020 (Virtual event)

Organised by DIA Read more
 
 
 
   

What we are reading
 
To overcome COVID-19, we need to show leadership on seasonal flu vaccination
On 14 October 2020 (Euractiv)

As we approach the 2020-2021 winter season, we are facing a potential “twindemic” of COVID-19 and seasonal flu. Read more
Can the coronavirus bring back Europe’s pharmaceutical factories?
On 12 October 2020 (Politico)

If the EU wants more drugs manufacturing independence, it may have to pay extra for it. Read more
When will covid-19 vaccines be available?
On 08 October 2020 (Vaccines Today)

Interview: Dr Melanie Saville, Director of Vaccine Development at CEPI, says demand will outstrip supply in 2021’ Read more

About the EFPIA newsletter

The European Federation of Pharmaceutical Industries and Associations (EFPIA) represents the pharmaceutical industry operating in Europe. Through its direct membership of 37 national associations and 40 leading pharmaceutical companies, EFPIA is the voice on the EU scene of 1,900 companies committed to researching, developing and bringing to patients new medicines that will improve health and the quality of life around the world.
Tel: +32 (0)2 626 25 55
E-mail:Communications@efpia.eu
EFPIA 2024 All rights reserved Disclaimer